Oxford, UK – 21 June 2016. OGT, The Molecular Genetics Company, has further expanded its extensive catalog of fluorescence in situ hybridization (FISH) products with 9 new CytoCell® probes. The range now includes ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe Aqua and Chromosome 15 Alpha Satellite Probe Red. These cost-effective and quality-assured probes produce specific, high-intensity signals with excellent contrast and minimal background for the utmost confidence in results. Optimized for use on common sample types, the probes are also pre-mixed in hybridization buffer, increasing ease of use and reducing errors in the laboratory.
Highlighting OGT’s renowned customer service, the new additions to the range have been developed in response to high customer demand via the CytoCell myProbes® FISH probes service. This custom probe design and manufacturing service enables OGT customers to purchase unique, fully quality-assured FISH probes for virtually any sequence in the entire human genome using the proprietary CytoCell BAC clone collection.
Faidra Partheniou, Hematology product manager at OGT explained, ‘These new probes are a real testament to the way OGT listens and responds to customer needs. We had a lot of people requesting these genes via our myProbes service so we wanted to make them readily available. Our dedicated customer support also ensures that we’re consistently there for our customers with expert advice and evaluation support. OGT offers the largest portfolio of FISH probes available and we look forward to announcing further new probes in the near future.’
The new additions to the CytoCell probe range are currently only available within North America as analyte specific reagents (ASRs), analytical and performance characteristics are not established. CE-marked IVD versions for sale in Europe are anticipated.
About OGT
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
OGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx detects clinically relevant rearrangements that occur in patients with acute leukemia, providing a robust, accessible, rapid turnaround test for KMT2Ar detection.
Read
OGT will be moving from plastic packaging to new, sustainable packaging for CytoCell products, an important step forward in our ongoing environmental efforts.
Read
Expansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
Read
CytoCell® University offers extensive FISH expertise and reaffirms commitment to customer support and training.
Read
Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.
Read
During these unprecedented times, OGT remains committed and ready to support you...
Read
MDSAP certification of new Cambridge facility smooths path to future IVD approvals.
Read
State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.
Read
Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.
Read
This year, OGT was proud to send CytoCell Product Manager Alex Hobbs to join the team of Sysmex runners representing Sysmex EMEA, APAC and JEA.
Read
Following successful European rollout, more customers to benefit from enhanced local sales and support services.
Read
Customers to benefit from Sysmex’s extensive operational footprint.
Read
On 1st April 2018 Dr John Anson took over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board.
Read
Sysmex, a Japanese in vitro diagnostic company, will acquire all of OGT’s shares, gaining access to OGT’s genetic analysis technologies and expertise in the cytogenetics domain.
Read
Addition of three new sarcoma probes produces largest portfolio on the market.
Read
Significant expansion of CytoCell® hematology range underlines OGT's position as the one-stop-shop for high-quality fluorescence in situ hybridization (FISH) probes.
Read
CytoCell® ROS1 Plus Breakapart and RET Breakapart probes specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer — non-small cell lung cancer (NSCLC).
Read
New CE-IVD labelled CytoCell® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit consistently delivers bright, specific signals with minimal background
Read
New additions to the CytoCell® range include-quality pathology FISH probes for 1q25, 1p36, 19p13, 19q13, ROS1-GOPC and RET.
Read
The award recognizes OGT’s acquisition of Cambridge-based Cytocell Limited (CytoCell), a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.
Read
New and existing CytoCell® customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure.
Read
Acquisition expands OGT’s genomic medicine offering, with CytoCell’s portfolio of fluorescence in situ hybridization (FISH) probes complementing OGT’s CytoSure cytogenetics array and NGS products.
Read
New office enables OGT to provide hands-on technical support and training to its existing US customers, and to take advantage of opportunities to develop the business further.
Read
OGT's Oxford, UK headquarters has been certified to BS EN ISO 9001:2008 by the British Standards Institution (BSI), one of the world’s leading certification bodies.
Read
Visit International site
Visit USA site
